NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development
International Journal of Molecular Sciences · 31.05.2024 · 25 (11) · 6078
DOI: 10.3390/ijms25116078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.05.2024. Verfasst von Inamul Haque und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Service, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Drug Discovery, Anticonvulsants, Epilepsy. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Department of the Kansas City VA Medical Center (KCVAMC) and Midwest Veterans Biomedical Research Foundation (MVBRF) at KCVAMC.
Abstract (Originalsprache)
Epilepsy is one of the most prevalent and serious brain disorders and affects over 70 million people globally. Antiseizure medications (ASMs) relieve symptoms and prevent the occurrence of future seizures in epileptic patients but have a limited effect on epileptogenesis. Addressing the multifaceted nature of epileptogenesis and its association with the Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome-mediated neuroinflammation requires a comprehensive understanding of the underlying mechanisms of these medications for the development of targeted therapeutic strategies beyond conventional antiseizure treatments. Several types of NLRP3 inhibitors have been developed and their effect has been validated both in in vitro and in vivo models of epileptogenesis. In this review, we discuss the advances in understanding the regulatory mechanisms of NLRP3 activation as well as progress made, and challenges faced in the development of NLRP3 inhibitors for the treatment of epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Development Service, Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
- Department of Math, Science and Business Technology, Kansas City Kansas Community College, Kansas City, KS 66112, USA.
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Drug Discovery Program, Midwest Veterans' Biomedical Research Foundation, KCVA Medical Center, Kansas City, MO 64128, USA.
- Renal Research Laboratory, Kansas City VA Medical Center, Kansas City, MO 64128, USA.
- Division of Neurology, Kansas City VA Medical Center, Kansas City, MO 64128, USA.
ORCID-Profile: Inamul Haque, Pritam Thapa, Ram Sharma
Förderung
- Research Department of the Kansas City VA Medical Center (KCVAMC) and Midwest Veterans Biomedical Research Foundation (MVBRF) at KCVAMC
Zitieren
APA
Haque, I., Thapa, P., Burns, D. M., Zhou, J., Sharma, M., Sharma, R., & Singh, V. (2024). NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development. International Journal of Molecular Sciences, 25(11), 6078. https://doi.org/10.3390/ijms25116078
Vancouver
Haque I, Thapa P, Burns DM, Zhou J, Sharma M, Sharma R, et al. NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development. International Journal of Molecular Sciences. 2024;25(11):6078. doi:10.3390/ijms25116078
BibTeX
@article{Haque2024,
author = {Haque, Inamul and Thapa, Pritam and Burns, Douglas M and Zhou, Jianping and Sharma, Mukut and Sharma, Ram and Singh, Vikas},
title = {NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {11},
pages = {6078},
doi = {10.3390/ijms25116078}
}
EUVIMED